Poster note: Target discovery program in systemic sclerosis
Posted: 14 September 2016 | Charles River Laboratories | No comments yet
Novel candidate drug targets for systemic scleroderma were identified using RNAi in phenotypic assays in scleroderma patient-derived fibroblasts…
This poster outlines a study to identify and validate novel candidate drug targets using RNAi in phenotypic assays in systemic sclerosis patient-derived fibroblasts.
A high throughput primary screen measuring the reversion of myofibroblasts was developed to screen Charles River’s SilenceSelect® adenoviral shRNA library (~21,000 shRNAs screened). Inhibition of aSMA mRNA expression was measured via fluorescence in situ hybridization (FISH), and ~550 shRNAs were selected for rescreen. Follow on 2D and 3D validation assays including gel contractility, impedance and skin equivalent (SE) are described.
This poster note is restricted - login or subscribe free to access
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related content from this organisation
- bit.bio raises $103 million in first close of Series B financing
- Cell-based assays market set to exhibit CAGR of 8.5 percent
- Under the microscope: CROs and microplate reader requirements
- Charles River Laboratories continues commitment to oncology drug discovery
- Charles River to present collaborative methods at Neuroscience 2018
Related topics
Drug Discovery Processes, Drug Targets, Screening
Related organisations
Charles River Laboratories